中文 | English
Return
Total: 8 , 1/1
Show Home Prev Next End page: GO
MeSH:(Protein-Tyrosine Kinase/immunology/*metabolism)

1.Immunoreactivity of CD99 in Non-Hodgkin's Lymphoma: Unexpected Frequent Expression in ALK-positive Anaplastic Large Cell Lymphoma.

Chang Ohk SUNG ; Young H KO ; Sanghui PARK ; Kihyun KIM ; Wonseog KIM

Journal of Korean Medical Science 2005;20(6):952-956

2.A Case of Primary Gastric CD30-Positive Anaplastic Large-Cell Lymphoma.

Hun Ho SONG ; Gwang Ho BAIK ; Jung Hye KWON ; Keun Seok LEE ; Young Hee CHOI ; Kyung Chan CHOI ; Young Eui PARK

Journal of Korean Medical Science 2005;20(6):1062-1065

3.Research progress on prognostic markers of chronic lymphocytic leukemia.

Jie MAO ; Zheng-rong MAO ; Ren ZHOU

Journal of Zhejiang University. Medical sciences 2010;39(3):250-256

4.Prognostic factors for chronic lymphocytic leukemia with typical and atypical immunophenotype.

Xin CAO ; Wei XU ; Yu-Jie WU ; Chun QIAO ; Qiong LIU ; Lei FAN ; Kou-Rong MIAO ; Jian-Yong LI

Chinese Journal of Hematology 2009;30(7):450-453

5.Abnormality of serum immunoglobulin in peripheral blood of patients with chronic lymphocytic leukemia.

Yuan-Dong ZHU ; Wei XU ; Kou-Rong MIAO ; Xin CAO ; Lei FAN ; Qiong LIU ; Lin YAO ; Yu-Jie WU ; Min HONG ; Jian-Yong LI

Journal of Experimental Hematology 2009;17(5):1159-1162

6.Progress in the study of allergic disease drugs targeting on IgE/FcepsilonRI signaling pathway.

Zhong-cheng LIU ; Hai-lang SHI ; Yan-fen ZHANG ; Li-jun ZHAO

Acta Pharmaceutica Sinica 2011;46(10):1161-1166

7.Design and expression of an inhibitor for HIV-1 targeting dendritic cell.

Meng ZHAO ; Qing XU ; Jiyun YU ; Yunzhou YU

Chinese Journal of Biotechnology 2011;27(8):1191-1197

8.Relationship between epithelial-immunologic cells transdifferentiation and pseudoepitheliomatous granuloma lesion.

Du-yin JIANG ; Xiao-bing FU ; Wei CHEN ; Tong-zhu SUN ; Zhi-yong SHENG

Chinese Journal of Surgery 2004;42(7):400-405

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 8 , 1/1 Show Home Prev Next End page: GO